title: High expression of serum miR-17-5p associated with poor prognosis in patients with hepatocellular carcinoma.
abstract: BACKGROUND
  MicroRNAs (miRNAs) have been shown to play pivotal roles in diverse biological processes. Altered expressions of miR-17-5p in several tumor types have been reported. However, the expression and clinical significance of serum miR-17-5p in patients with hepatocellular carcinoma (HCC) are unclear.
  
  
  METHODS
  The expression of miR-17-5p was measured in the serum of paired pre-operative and post-operative groups (n=96) as well as non-relapsed and relapsed groups (n=40) by qRT-PCR. Further study was performed to analyze the correlation of miR-17-5p expression with clinicopathologic variables and the relationship between miR-17-5p expression and the prognosis of HCC patients.
  
  
  RESULTS
  The expression of serum miR-17-5p was significantly down-regulated in post-operative group and upregulated in relapsed group. Moreover, the expression of serum miR-17-5p was remarkably associated with the metastasis status and TNM stages (P<0.0001). Importantly, Kaplan-Meier curve analysis revealed that HCC patients with high expression of serum miR-17-5p had a significantly shortened overall survival (P=0.003). Univariate and Multivariable Cox regression analysis indicated that the expression of serum miR-17-5p was an independent risk factor for overall survival (P=0.005 and P=0.043, respectively).
  
  
  CONCLUSIONS
  The level of serum miR-17-5p is associated with development of HCC and can serve as a non-invasive biomarker for the prognostic prediction of HCC patients.
authors.affiliation: Wenzhou Key Laboratory of Surgery, The First Affiliated Hopsital of Wenzhou Medical College, Wenzhou, China.
authors.forename: Jianjian
authors.initials: J
authors.lastname: Zheng
authors.forename: Peihong
authors.initials: P
authors.lastname: Dong
authors.forename: Shenmeng
authors.initials: S
authors.lastname: Gao
authors.forename: Ni
authors.initials: N
authors.lastname: Wang
authors.forename: Fujun
authors.initials: F
authors.lastname: Yu
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics*; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000235:genetics* / Q000401:mortality / Q000556:secondary / Q000628:therapy; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000097:blood / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D008297:Male; D035683:MicroRNAs / Q000097:blood*; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome; D015854:Up-Regulation
chemical_list: D014408:Biomarkers, Tumor; C524941:MIRN17 microRNA, human; D035683:MicroRNAs